首页 | 本学科首页   官方微博 | 高级检索  
     

细辛脑联合莫西沙星治疗成人支原体肺炎的临床研究
引用本文:胡英,杨永红. 细辛脑联合莫西沙星治疗成人支原体肺炎的临床研究[J]. 现代药物与临床, 2017, 32(3): 451-454. DOI: 10.7501/j.issn.1674-5515.2017.03.022
作者姓名:胡英  杨永红
作者单位:重庆市巴南区第二人民医院呼吸内科,重庆,400054
摘    要:目的探讨细辛脑注射液联合盐酸莫西沙星氯化钠注射液治疗成人支原体肺炎的临床疗效。方法选取2015年9月—2016年9月在重庆市巴南区第二人民医院进行治疗的成人支原体肺炎患者88例,根据治疗方案的差别分为对照组和治疗组,每组各44例。对照组静脉滴注盐酸莫西沙星氯化钠注射液,0.4 g/次,1次/d。治疗组在对照组基础上静脉滴注注射用细辛脑,24 mg加入到5%葡萄糖溶液250 m L中,2次/d。两组患者均治疗2周。观察两组的临床疗效,比较临床症状消失时间和血清学指标。结果治疗后,对照组和治疗组的总有效率分别为81.82%、97.73%,两组比较差异有统计学意义(P0.05)。治疗后,治疗组体温恢复时间、咳嗽消失时间、肺部啰音消失时间均比对照组明显缩短,两组比较差异有统计学意义(P0.05)。治疗后,两组血清白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、碱性成纤维细胞生长因子(b FGF)和降钙素原(PCT)水平均显著下降,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标的下降程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。结论细辛脑注射液联合盐酸莫西沙星氯化钠注射液治疗成人支原体肺炎具有较好的临床疗效,可明显改善临床症状,调节血清学指标,具有一定的临床推广应用价值。

关 键 词:注射用细辛脑  盐酸莫西沙星氯化钠注射液  支原体肺炎  临床症状消失时间  血清学指标
收稿时间:2016-11-02

Clinical study on asarone combined with moxifloxacin in treatment of mycoplasma pneumonia in adults
HU Ying and YANG Yong-hong. Clinical study on asarone combined with moxifloxacin in treatment of mycoplasma pneumonia in adults[J]. Drugs & Clinic, 2017, 32(3): 451-454. DOI: 10.7501/j.issn.1674-5515.2017.03.022
Authors:HU Ying and YANG Yong-hong
Affiliation:Department of Respiratory Medicine, Banan Second People''s Hospital of Chongqing, Chongqing 400054, China;Department of Respiratory Medicine, Banan Second People''s Hospital of Chongqing, Chongqing 400054, China
Abstract:Objective To evaluate the clinical efficacy of Asarone for injection combined with Moxifloxacin Hydrochloride and Sodium Chloride Injection in treatment of mycoplasma pneumonia in adults.Methods Patients (88 cases) with mycoplasma pneumonia in Banan Second People's Hospital of Chongqing from September 2015 to September 2016 were enrolled in this study. According to the difference treatment plan, patients were randomly divided into control and treatment groups, and each group had 44 cases. Patients in the control group were iv administered with Moxifloxacin Hydrochloride and Sodium Chloride Injection, 0.4 g/time, once daily. Patients in the treatment group were iv administered with Asarone for injection on the basis of the control group, 24 mg added into 5% glucose solution 250 mL, twice daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and clinical symptom disappearance time and serological indexes in two groups were compared.Results After treatment, the clinical efficacies in the control and treatment groups were 81.82% and 97.73%, respectively, and there was difference between two groups (P < 0.05). After treatment, the body temperature recovery time and the disappearance time of cough and pulmonary rales in the treatment group were shorter than those in the control group, and there was difference between two groups (P < 0.05). After treatment, the levels of IL-6, TNF-α, bFGF, and PCT in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05).Conclusion Asarone for injection combined with Moxifloxacin Hydrochloride and Sodium Chloride Injection has clinical cutive effect in treatment of mycoplasma pneumonia in adults, can significantly improve clinical symptoms, and regulate serological indexes, which has a certain clinical application value.
Keywords:Asarone for injection  Moxifloxacin Hydrochloride and Sodium Chloride Injection  mycoplasma pneumonia  clinical symptom disappearance time  serological index
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号